Is there a way to get rid of allergies permanently?

The honest answer is: immunotherapy produces lasting remission in most people who complete the full course, but "permanently" overstates what the evidence supports. Here is exactly what the long-term data shows and why the distinction between "cure" and "sustained remission" matters.

Immunotherapy works through a three-phase immune shift. In Phase 1 (weeks 1-12), allergen exposure under the tongue activates dendritic cells that begin producing regulatory signals instead of pro-inflammatory ones. In Phase 2 (months 3-12), regulatory T cells expand and begin suppressing the IgE-driven allergic response, while IgG4 blocking antibodies rise to intercept allergens before they trigger mast cells. In Phase 3 (years 1-3+), the immune system reaches a stable tolerogenic state where allergen exposure no longer triggers significant IgE production. This three-year remodeling process explains why shorter treatment courses fail to produce lasting benefit — a 2022 JACI consensus review confirmed that 2 years were "efficacious but insufficient to induce long-term tolerance" (Penagos and Durham, PMID: 35818157).

The strongest long-term SLIT data comes from two landmark studies. Marogna et al. (2004, PMID: 15461603) followed 511 patients through 3 years of treatment, documenting progressive improvement: clinical symptom scores dropped approximately 50% at year 1, 54% at year 2, and 63% at year 3 compared to baseline.

The same research group published a 15-year follow-up (Marogna et al. 2010, PMID: 20934206) comparing different treatment durations. Patients who completed 3 years maintained clinical benefit for approximately 7 years after stopping. Those who completed 4 years maintained benefit for approximately 8 years. This dose-response relationship — more years of treatment yielding more years of remission — is the strongest evidence that immunotherapy produces genuine immune remodeling, not just temporary suppression.

For immunotherapy's ability to prevent new conditions: the PAT study followed 205 children with pollen allergy for 10 years after 3 years of immunotherapy (Jacobsen et al. 2007, PMID: 17620073). Only 25% of treated children developed asthma compared to 45% of untreated controls — a preventive effect persisting at least 7 years after treatment ended.

Three caveats prevent allergists from using the word "cure." First, not everyone responds: 20-30% of patients who complete 3-5 years do not achieve sustained remission. Second, some patients relapse years later — particularly after new or intensified allergen exposure. Third, immunotherapy works best for specific sensitizations (pollen, dust mite, mold, pet dander) but cannot address all allergic conditions equally.

The Cochrane review (Radulovic et al. 2010) of SLIT for allergic rhinitis (, PMID: 21154351) found a standardized mean difference of -0.49 for symptom scores across 60 RCTs with 4,589 patients — statistically significant and clinically meaningful, but not 100% resolution. The most accurate framing: immunotherapy produces durable immune tolerance in most patients, sustained for years after treatment, but individual results vary.

Save your money if your allergies are mild and seasonal — two weeks of sneezing each spring managed by $15/month generic cetirizine does not warrant a 3-5 year immunotherapy commitment. Save your money if you have non-allergic rhinitis (vasomotor rhinitis, gustatory rhinitis) — immunotherapy only works on IgE-mediated allergy, and more than 60% of rhinitis in adults over 50 has a non-allergic etiology. Save your money if your only trigger is easily avoidable — a specific workplace chemical, a friend's cat you see twice a year. Immunotherapy makes sense when allergies are perennial, moderate-to-severe, multi-allergen, or inadequately controlled by OTC medications.